Bicara Therapeutics releases corporate deck highlighting ficerafusp alfa EGFR-TGF-β program in HPV-negative head and neck cancer
BCAX•Cash position and development plan
Cash, cash equivalents, and marketable securities totaled $497.3 million as of June 30, 2026; runway was projected into 1H 2029.
The development plan included the FORTIFI-FLEX alternate dosing study, along with additional signal-seeking in EGFR x TGF-β biology tumors such as cSCC, anal canal cancer, and mCRC.
Corporate deck highlights ficerafusp alfa in HPV-negative head and neck cancer
Bicara highlighted ficerafusp alfa (FICERA), an EGFR-directed antibody fused to a TGF-β ligand trap, as its lead oncology asset.
Pivotal FORTIFI-HN01 in 1L recurrent or metastatic HPV-negative HNSCC targeted substantial enrollment by year-end, with interim topline data expected in mid-2027.
Phase 1b in 1L R/M HPV-negative HNSCC showed confirmed ORR of 48%-57% across regimens; median PFS of 6.9-12.7 months; and median OS of 21.3 months at 1500mg QW.
